EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases

Loris Riccardo Lopetuso iD, Claudia Cuomo, Irene Mignini, Antonio Gasbarrini iD, Alfredo Papa iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24098187 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Loris Riccardo Lopetuso und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Diagnosis and Treatment of Digestive Diseases, CEMAD, Gastroenterology Department, Fondazione Policlinico Gemelli, IRCCS, 00168 Rome, Ital…. Hauptthemen laut MEDLINE: Autoimmune Diseases, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti-tumour necrosis factor (TNF)-α agents have been increasingly used to treat patients affected by inflammatory bowel disease and dermatological and rheumatologic inflammatory disorders. However, the widening use of biologics is related to a new class of adverse events called paradoxical reactions. Its pathogenesis remains unclear, but it is suggested that cytokine remodulation in predisposed individuals can lead to the inflammatory process. Here, we dissect the clinical aspects and overall outcomes of autoimmune diseases caused by anti-TNF-α therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autoimmune DiseasesInflammatory Bowel DiseasesHumansAdalimumabAntibodies, MonoclonalCertolizumab PegolEtanerceptTumor Necrosis Factor InhibitorsAntibodies, Monoclonal, HumanizedTumor Necrosis Factor-alphaNecrosisInfliximab

Stichwörter der Autor:innen

adalimumabautoimmune diseasescertolizumab pegoletanerceptgolimumabinflammatory bowel diseaseinfliximabparadoxical reactions

Substanzen

AdalimumabAntibodies, MonoclonalCertolizumab PegolEtanerceptTumor Necrosis Factor InhibitorsAntibodies, Monoclonal, HumanizedTumor Necrosis Factor-alphaInfliximab

Autor:innen und Institutionen

  • Center for Diagnosis and Treatment of Digestive Diseases, CEMAD, Gastroenterology Department, Fondazione Policlinico Gemelli, IRCCS, 00168 Rome, Italy.
  • Department of Medicine and Ageing Sciences, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.
  • Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.
  • Department of Translational Medicine and Surgery, School of Medicine, Catholic University, 00168 Rome, Italy.

ORCID-Profile: Loris Riccardo Lopetuso, Antonio Gasbarrini, Alfredo Papa

Zitieren

APA

Lopetuso, L. R., Cuomo, C., Mignini, I., Gasbarrini, A., & Papa, A. (2023). Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24098187

Vancouver

Lopetuso LR, Cuomo C, Mignini I, Gasbarrini A, Papa A. Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24098187

BibTeX
@article{Lopetuso2023,
  author = {Lopetuso, Loris Riccardo and Cuomo, Claudia and Mignini, Irene and Gasbarrini, Antonio and Papa, Alfredo},
  title = {Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24098187}
}
Kostenlos starten →